Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Go back to Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

RBC Capital on WAVE Life Sciences (WVE): 'We appreciate the progress but remain cautious'

March 6, 2024 4:18 PM EST

RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $5.00 price target on WAVE Life Sciences (NASDAQ: WVE).

The analyst comments "Next data is HD in Q2 and 20% allele specific KD is the bogey for a go/no-go decision and TAK... More